David Bredt, Chief Scientific Officer at Rapport Therapeutics, Inc. (RAPP), sold 16,204 shares at $29.95 ($486K) on 2025-12-15, disclosed to the SEC on 2025-12-16.
Scheduled sale ($486k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.95 | 7,704 | $231K | 47.5% |
| 2 | $29.95 | 7,704 | $231K | 47.5% |
| 3 | $30.68 | 796 | $24K | 5.0% |
| Total | $29.99 avg | 16,204 | $486K | 100% |
| Filing → |
| RAPP | SELL | 2026-01-05 | $395K | — | Filing → |
| RAPP | SELL | 2025-11-18 | $428K | — | Filing → |
| RAPP | SELL | 2025-10-16 | $410K | — | Filing → |